false
0001041024
0001041024
2024-07-12
2024-07-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 12, 2024
Rockwell
Medical, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
000-23661 |
38-3317208 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
30142
S. Wixom Road, Wixom, Michigan 48393
(Address of principal executive offices, including
zip code)
(248) 960-9009
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each Class | |
Trading
Symbol | |
Name of Each exchange on which
registered |
Common Stock, par value $0.0001 | |
RMTI | |
Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 1.01 | Entry into a Material Definitive Agreement. |
On July 12, 2024, Rockwell Medical, Inc.
(the “Company”) and Evoqua Water Technologies LLC, a Delaware limited liability company (“Evoqua”), executed Amendment
No. 1 to the Asset Purchase Agreement (the “Amendment”), dated as of July 10, 2023, by and between the Company and
Evoqua (the “Purchase Agreement”). The Amendment clarifies certain terms regarding physical assets covered by the Purchase
Agreement and provides for an extended payment schedule for the deferred payments due by the Company to Evoqua and a partial reduction
in such payments as follows:
| · | $2,500,000 (the “First Deferred Payment”), which shall be partially offset $322,260 to reimburse
the Company for certain expenses incurred following the closing of the Purchase Agreement, resulting in a reduction of the First Deferred
Payment to $2,177,740, and which shall be paid in four quarterly installments through April 2025; and |
| · | $2,500,000, which shall be payable to Evoqua in four quarterly installments from July 10, 2025 through
April 10, 2026. |
The foregoing description of the Amendment and
the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text
of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K (this “Form 8-K”) and incorporated
herein by reference.
| Item 7.01 | Regulation FD Disclosure. |
Gross Margin Guidance for 2024
On July 15, 2024, Mark Strobeck, the Company’s Chief Executive
Officer, was interviewed by HC Wainwright as part of the 2024 Annual Kidney Conference. During such interview, Dr. Strobeck reconfirmed
the Company’s previously provided guidance of gross margin for 2024 between 14% and 16% (noting that Dr. Strobeck inadvertently
referred to gross margin guidance in the range of 13% to 15%, which was actually a reference to the Company’s previously issued gross
profit guidance of $13 to $15 million).
As noted in the Company’s first quarter earnings release, the
Company has excluded deferred revenue from the first quarter calculation of gross margin. This gross margin measure is a non-GAAP (as
defined below) financial measure. The Company has provided reconciliations to the GAAP measures at the end of the press release issued
by the Company on May 14, 2024, announcing gross margin guidance for 2024. Adjusted gross margin is used by the Company to understand
growth within its hemodialysis concentrates business by excluding a one-time item that is not indicative of its core operating performance.
Adjusted gross margin should not be considered in isolation of, or
as an alternative to, measures prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”).
Other companies, including companies in the same industry, may calculate similarly titled non-GAAP financial measures differently or may
use other measures to evaluate their performance, all of which could reduce the usefulness of adjusted gross margin as a tool for comparison.
There are a number of limitations related to the use of this non-GAAP financial measure rather than the most directly comparable financial
measures calculated in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross margin
alongside other financial performance measures, including net loss and other GAAP results. Adjusted gross margin enables us to understand
growth within our hemodialysis concentrates business by excluding a one-time item that is not indicative of our core operating performance.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking
statements” within the meaning of the federal securities laws. Words such as, “may,” “might,” “will,”
“should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,”
“could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,”
“forecast,” “project,” “intend,” “look forward to,” “remain confident,” “feel
confident,” “guidance,” or the negative of these terms, and similar expressions, or statements regarding intent, belief,
or current expectations, are forward-looking statements. These statements include (without limitation) statements regarding gross margin
and financial guidance for 2024. While the Company believes these forward-looking statements are reasonable, undue reliance should not
be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation,
those set forth in the Company’s SEC filings), many of which are beyond our control and subject to change. Actual results could
be materially different. Risks and uncertainties include but are not limited to those risks more fully discussed in the “Risk Factors”
section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated
in any subsequent reports filed with the SEC. The Company expressly disclaims any obligation to update our forward-looking statements,
except as may be required by law.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
EXHIBIT INDEX
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ROCKWELL MEDICAL, INC. |
|
|
|
Date: July 15, 2024 |
By: |
/s/ Mark Strobeck |
|
|
Mark Strobeck, Ph.D. |
|
|
President and Chief Executive Officer |
Exhibit 10.1
Amendment
No. 1 to Asset Purchase Agreement
This
Amendment No. 1 to Asset Purchase Agreement (this “Amendment”) is made as of July 12, 2024, by
and between Evoqua Water Technologies LLC, a Delaware limited liability company (“Seller”), and Rockwell Medical, Inc.,
a Delaware corporation (“Purchaser” and together with Seller, the “Parties”). Capitalized terms
used and not otherwise defined herein shall have the meanings accorded to such terms under the Agreement (as defined below).
BACKGROUND
WHEREAS,
the Parties are each party to that certain Asset Purchase Agreement, dated as of July 10, 2023 (the “Agreement”);
WHEREAS,
Section 10.2 of the Agreement provides that the Agreement may be amended by an agreement in writing executed by the Parties; and
Whereas,
the Parties wish to make certain changes to the provisions related to the Purchase Price, including to account for payments made by Rockwell
to dispose of expired Inventory.
AGREEMENT
NOW
THEREFORE, in consideration of the foregoing premises and certain other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereby agree as follows:
| 1. | Amendment to Section 1.1(d). Section 1.1(d) of the Agreement is hereby amended and
restated to read in its entirety as follows: |
(d) all manufacturing equipment,
supplies and other tangible personal property used primarily in the Concentrates Business, including the manufacturing equipment, supplies
and other tangible personal property listed on Disclosure Schedule 1.1(d) (the “Equipment”); provided, however, that
Equipment listed on Disclosure Schedule 1.1(d) that cannot be physically separated from its existing site and physically relocated
to Purchaser’s site using commercially reasonable efforts (the “Undeliverable Equipment”) shall not be considered an
Acquired Asset and Seller shall have no obligation to reimburse Purchaser for such Undeliverable Equipment;
| 2. | Amendment to Section 2.1. Section 2.1 of the Agreement is hereby amended and restated
to read in its entirety as follows: |
“2.1 Purchase
Price. In consideration of the sale and transfer of the Acquired Assets and assumption of the Assumed Liabilities, Purchaser shall
pay and deliver to Seller an aggregate purchase price amount equal to sixteen million dollars ($16,000,000) plus the Final Inventory Amount
(collectively, the “Purchase Price”). The Purchase Price shall be paid by Purchaser to Seller as follows:
(a) at
Closing, an amount equal to eleven million dollars ($11,000,000) (the “Closing Purchase Price”) plus the Estimated
Inventory Amount, by wire transfer of immediately available funds to an account designated by Seller;
(b) two
million five hundred thousand dollars ($2,500,000), (the “First Deferred Payment”), payable by wire transfer of immediately
available funds to an account designated by Seller; provided, however, that pursuant to Section 8.4(d) the First Deferred Payment
shall be partially offset by an amount equal to three hundred twenty-two thousand, two hundred sixty dollars ($322,260) to reimburse Purchaser
for expenses incurred by Purchaser following the Closing related to the disposal of expired Inventory (the “Expired Inventory”),
resulting in a reduction of the First Deferred Payment to two million one hundred seventy-seven thousand seven hundred forty dollars ($2,177,740)
(the “Adjusted First Deferred Payment”). Such Adjusted First Deferred Payment shall be made in in four (4) installments
payable as follows: $653,322 on July 12, 2024; $653,322 on October 10, 2024; $435,548 on January 10, 2025; and $435,548
on April 10, 2025; and
(c) two
million five hundred thousand dollars ($2,500,000) (the “Second Deferred Payment” and collectively with the Adjusted
First Deferred Payment, the “Deferred Payments”), payable by wire transfer of immediately available funds to an account
designated by Seller in four (4) installments payable as follows: $750,000 on July 10, 2025; $750,000 on October 10, 2025;
$500,000 on January 12, 2026; and $500,000 on April 10, 2026.”
3. Release.
In consideration of the foregoing amendments, Purchaser, on behalf of itself and its affiliates, their respective successors and assigns,
and their respective employees, representatives, officers, directors, and shareholders, hereby fully releases and forever discharges Seller
and its affiliates, their respective successors and assigns, and their respective employees, representatives, officers, directors, and
shareholders from any and all claims, demands, and causes of action, in law, equity, or otherwise, whether asserted or unasserted, known
or unknown, suspected or unsuspected, based in contract, tort, statute, or regulation (whether state, local, foreign, federal, statutory,
regulatory, common, or other law or rule), or otherwise, contingent or non-contingent, based on, arising out of, relating to, or concerning,
in whole or in part, any failure to deliver the Undeliverable Equipment or Purchaser’s disposal of Expired Inventory.
4. Effect
of this Amendment; Counterparts. Except as specifically modified herein, the Agreement remains in full force and effect. This Amendment
may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one
and the same instrument, with the same effect as if the signatures thereto were in the same instrument. Article X of the Agreement
is hereby incorporated by reference mutatis mutandis.
[Remainder of page intentionally left blank]
IN WITNESS WHEREOF, the Parties have executed this
Amendment as of the date first written above.
|
PURCHASER: |
|
|
|
Rockwell Medical, Inc. |
|
|
|
|
|
By: |
/s/ MARK STROBECK |
|
Name: Mark Strobeck, Ph.D |
|
Title: President and CEO |
|
|
|
|
|
SELLER: |
|
|
|
EVOQUA WATER TECHNOLOGIES LLC |
|
|
|
|
|
By: |
/s/ RODNEY MCNELLY |
|
Name: Rodney McNelly |
|
Title: VP WSS North America |
[Signature Page to Amendment No. 1
to Asset Purchase Agreement]
v3.24.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Rockwell Medical (NASDAQ:RMTI)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Rockwell Medical (NASDAQ:RMTI)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024